We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nan.12781 | DOI Listing |
Publication Analysis
Top Keywords
disease treated
8
low doses
8
neuropathology patient
4
patient alzheimer
4
alzheimer disease
4
treated low
4
doses verubecestat
4
verubecestat report
4
report neuropathological
4
neuropathological examination
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!